Glatiramer acetate - Important Safety Information from Teva Pharmaceuticals Ireland and Viatris limited as approved by the HPRA (14.08.24)

Notice type: 3rd Party Publications

Date: 14/08/2024




Problem Or Issue:

Important Safety Information from Teva Pharmaceuticals Ireland and Viatris Limited regarding Glatiramer acetate: Anaphylactic reactions may occur months up to years after treatment initiation

Important Safety Information ­–  Glatiramer acetate  


« Back